Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) FCF Margin (2016 - 2026)

Pharma-Bio Serv's FCF Margin history spans 16 years, with the latest figure at 17.1% for Q1 2026.

  • For Q1 2026, FCF Margin rose 27.0% year-over-year to 17.1%; the TTM value through Jan 2026 reached 2.09%, up 1750.0%, while the annual FY2025 figure was 2.46%, 518.0% up from the prior year.
  • FCF Margin reached 17.1% in Q1 2026 per PBSV's latest filing, down from 12.99% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 30.47% in Q1 2024 to a low of 29.47% in Q2 2024.
  • Average FCF Margin over 5 years is 0.29%, with a median of 3.37% recorded in 2024.
  • Peak YoY movement for FCF Margin: tumbled -4870bps in 2024, then surged 3974bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 5.35% in 2022, then skyrocketed by 61bps to 8.62% in 2023, then tumbled by -139bps to 3.37% in 2024, then soared by 486bps to 12.99% in 2025, then tumbled by -232bps to 17.1% in 2026.
  • Per Business Quant, the three most recent readings for PBSV's FCF Margin are 17.1% (Q1 2026), 12.99% (Q4 2025), and 11.94% (Q3 2025).